Human Anti-VEGFA Recombinant Antibody (clone MIL60) (CAT#: HPAB-0169-WJ)
This product is a human IgG antibody targeting the human vascular endothelial growth factor (VEGF). This antibody can specifically recognize a human vascular endothelial growth factor (VEGF) antigen and can substantially inhibit tumor tissue neovascularization thereby inhibiting tumor growth.
Specific Inquiry
ELISA
Figure 1 MIL60 binding to VEGF.
(a) ELISA analysis of MIL60 binding the coated VEGF antigen. Avastin was set as a positive control. MIL60 showed similar antigen binding activity to that of Avastin.
Yang, J., Wang, Q., Qiao, C., Lin, Z., Li, X., Huang, Y., ... & Feng, J. (2014). Potent anti-angiogenesis and anti-tumor activity of a novel human anti-VEGF antibody, MIL60. Cellular & molecular immunology, 11(3), 285.
Neut
Figure 2 MIL60 binding to VEGF.
(b) Biofunction of MIL60 in neutralizing free VEGF in the cultural supernatant of SKOV3 cells. *P<0.05, versus IgG control. VEGF, vascular endothelial growth factor.
Yang, J., Wang, Q., Qiao, C., Lin, Z., Li, X., Huang, Y., ... & Feng, J. (2014). Potent anti-angiogenesis and anti-tumor activity of a novel human anti-VEGF antibody, MIL60. Cellular & molecular immunology, 11(3), 285.
Inhib
Figure 3 MIL60 inhibits VEGF-induced cell proliferation, migration and tube formation in vitro in HUVECs.
(a) Cell proliferation of HUVECs induced by VEGF was inhibited by MIL60 in a dose-dependent manner.
Yang, J., Wang, Q., Qiao, C., Lin, Z., Li, X., Huang, Y., ... & Feng, J. (2014). Potent anti-angiogenesis and anti-tumor activity of a novel human anti-VEGF antibody, MIL60. Cellular & molecular immunology, 11(3), 285.
IHC
Figure 4 MIL60 inhibits VEGF-induced cell proliferation, migration and tube formation in vitro in HUVECs.
(b and c) MIL60 inhibits the VEGF-induced migration of HUVECs. The MIL60 or Avastin antibodies were diluted to 0.08 µg/ml, 0.8 µg/ml and 8 µg/ml.
Yang, J., Wang, Q., Qiao, C., Lin, Z., Li, X., Huang, Y., ... & Feng, J. (2014). Potent anti-angiogenesis and anti-tumor activity of a novel human anti-VEGF antibody, MIL60. Cellular & molecular immunology, 11(3), 285.
WB
Figure 5 VEGF induces VEGFR2 phosphorylation and activation of the downstream signal cascade.
Pre-incubation of MIL60 and 50 ng/ml VEGF blocked its efficacy for activating key signal molecules such as VEGFR2, ERK, P38 and p65 in a dose-dependent manner. The MIL60 or Avastin antibodies were diluted to 0.04 µg/ml, 0.4 µg/ml and 4 µg/ml. VEGF, vascular endothelial growth factor.
Yang, J., Wang, Q., Qiao, C., Lin, Z., Li, X., Huang, Y., ... & Feng, J. (2014). Potent anti-angiogenesis and anti-tumor activity of a novel human anti-VEGF antibody, MIL60. Cellular & molecular immunology, 11(3), 285.
Specifications
- Host Species
- Human
- Type
- Human IgG
- Specificity
- Human VEGF
- Species Reactivity
- Human
- Clone
- MIL60
- Applications
- ELISA, Neut, Inhib, IHC, WB
- Related Disease
- Cancers
Product Property
- Purity
- >95% as determined by SDS-PAGE and HPLC analysis
- Concentration
- Please refer to the vial label for the specific concentration.
- Buffer
- PBS
- Preservative
- No preservatives
- Storage
- Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Applications
- Application Notes
- The VEGF antibody has been reported in applications of Enzyme-linked Immunosorbent Assay, Neutralization, Inhibition, Immunohistochemistry, Western Blot.
For ELISA: ELISA plates were coated with 0.5 µg/ml VEGF fusion protein at 4 °C overnight and then blocked with 1% bovine serum albumin (BSA) in phosphate-buffered saline (PBS) containing 0.05% Tween-20 for one hour at 37 °C. Diluted MIL60 or Avastin were added as the primary antibody and incubated for 2 h at 37 °C. After washing, HRP-conjugated goat anti-human IgG was incubated for one hour at room temperature. Binding signals were visualized using o-phenylenediamine dihydrochloride substrate and the light absorbance was measured using an ELISA reader at 492 nm. For competition ELISA, MIL60, Avastin or a negative control antibody (IgG) were individually mixed at increasing concentrations with an equal volume of the competitors. The antibody mixtures were added as the primary antibodies and all experiments were performed in triplicate.
For IHC: One week after the last treatment, the tumors of the mice were removed and fixed with 10% formaldehyde. Paraffin-embedded tissue sections were processed, deparaffinized, rehydrated and quenched of endogenous peroxidase activity. Sections were first stained with anti-CD31 antibody (dilution 1∶100) and then incubated with HRP-conjugated secondary antibody. Finally, the sections were developed with diaminobenzidine and counterstained with hematoxylin. Pictures were captured using an OLYMPUS BX5 microscope and an UPlanFL N digital camera (10×0.13 numeric aperture objective). Any single, brown-stained cell or cluster of EC that was clearly separated from adjacent microvessels, tumor cells and other connective tissue elements was considered a vessel. The number of CD31-position capillaries was counted from five randomly chosen fields.
For Western Blot: HUVECs were seeded in six-well plates at a density of 8×10⁵ cells/ml. After being serum-starved overnight, they were cultivated in serum-free ECM that was supplemented with 50 ng/ml VEGF and different concentrations of MIL60 or Avastin for 30 min. Thereafter, the supernatant of the cell lysate was subjected to SDS–PAGE analysis using a 12% gel and transferred onto a nitrocellulose membrane. The membrane was blocked with non-fat 5% milk for 1 h at room temperature and then incubated with various antibodies (dilution 1∶1000) overnight at 4 °C. After washing, the membranes were incubated with HRP-conjugated antibodies for an hour at room temperature, and the signals of the membrane were detected and visualized using an enhanced chemiluminescence detection system and autoradiography.
Target
- Alternative Names
- Vascular endothelial growth factor; VEGF
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Clone MIL60"
See other products for "VEGFA"
Humanized Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-H73 | Anti-Human VEGFA Recombinant Antibody (Vanucizumab) | WB, FC, IP, ELISA, Neut, FuncS, IF | VH - C-kappa - CH2 - CH3 _ V-lambda - CH1 _ H-GAMMA-1 _ L-kappa |
| TAB-307CQ | Human Anti-VEGFA Recombinant Antibody (TAB-307CQ) | Inhib | Human IgG |
| TAB-307CQ-S(P) | Human Anti-VEGFA Recombinant Antibody; scFv Fragment (TAB-307CQ-S(P)) | ELISA, Neut | Human scFv |
| TAB-307CQ-F(E) | Human Anti-VEGFA Recombinant Antibody; Fab Fragment (TAB-307CQ-F(E)) | ELISA, Neut | Humanized Fab |
| TAB-009ML | Anti-Human VEGFA Recombinant Antibody scFv Fragment (Brolucizumab) | ELISA, IHC, FC, IP, IF, Inhib | scFv, κ |
Immunotoxin
| CAT | Product Name | Application | Type |
|---|---|---|---|
| AGTO-L043L | anti-VEGFA immunotoxin Ng76 (scFv)-Luffin-β | Cytotoxicity assay, Functional assay |
Human Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-284CQ | Human Anti-VEGFA Recombinant Antibody (TAB-284CQ) | WB | Human antibody |
| TAB-304CQ | Anti-Human VEGFA Recombinant Antibody (2H1) | ELISA | Human antibody |
| TAB-305CQ | Anti-Human VEGFA Recombinant Antibody (2H1-32) | ELISA, WB | Human antibody |
| TAB-284CQ-S(P) | Human Anti-VEGFA Recombinant Antibody; scFv Fragment (TAB-284CQ-S(P)) | ELISA | Human scFv |
| TAB-465CQ | Anti-Human VEGFA Recombinant Antibody (Varisacumab) | ELISA, IHC, FC, IP, IF, FuncS | IgG1, κ |
Mouse Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-306CQ | Mouse Anti-VEGFA Recombinant Antibody (TAB-306CQ) | FuncS, Inhib | Mouse IgG |
| TAB-306CQ-S(P) | Mouse Anti-VEGFA Recombinant Antibody; scFv Fragment (TAB-306CQ-S(P)) | ELISA, Neut | Mouse scFv |
| TAB-306CQ-F(E) | Mouse Anti-VEGFA Recombinant Antibody; Fab Fragment (TAB-306CQ-F(E)) | ELISA, Neut | Mouse Fab |
Chicken IgY Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| BRD-0623MZ | Chicken Anti-VEGF Polyclonal IgY | WB | Chicken antibody |
Neutralizing Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| NEUT-2255CQ | Mouse Anti-VEGFA Recombinant Antibody (clone CBL198) | Neut, WB | Mouse IgG1 |
| NEUT-2256CQ | Rat Anti-Vegfa Recombinant Antibody (clone 2G11-2A05) | WB, Neut, ELISA, IHC, FuncS | Rat IgG2a, κ |
| NEUT-2257CQ | Mouse Anti-VEGFA Recombinant Antibody (clone 16F1) | WB, Neut | Mouse IgG2a |
| NEUT-2258CQ | Mouse Anti-VEGFA Recombinant Antibody (clone 4B2-8) | ELISA, Neut, WB | Mouse IgG1, κ |
| NEUT-2260CQ | Mouse Anti-VEGFA Recombinant Antibody (clone CBL737) | WB, ELISA, Neut | Mouse IgG2b |
Blocking Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| NEUT-2259CQ | Mouse Anti-VEGFA Recombinant Antibody (clone A.4.6.1) | ELISA, IP, WB, Block, FC, IHC | Mouse IgG1, κ |
| NEUT-2267CQ | Mouse Anti-VEGFA Recombinant Antibody (clone A15136B) | WB, Block | Mouse IgG2b, κ |
Rabbit Monoclonal Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MOR-3835 | Rabbit Anti-VEGFA Recombinant Antibody (clone DS3835AB) | FC, ICC, IF, IHC-P, IP, WB | Rabbit IgG |
| MOR-4758 | Rabbit Anti-Vegfa Recombinant Antibody (clone TH272DS) | WB | Rabbit IgG |
Single-domain Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MD-ZBF-YC024 | Camelid Anti-VEGFA Recombinant Single Domain Antibody (clone A80887) | ELlSA | Camelid VHH |
| HPAB-N0310-YC-VHNAR | Recombinant Shark Anti-VEGFA Single Domain Antibody (V32R) | ELISA, FC, WB | Shark vNAR |
| HPAB-N0311-YC-VHNAR | Recombinant Shark Anti-VEGFA Single Domain Antibody (V19) | ELISA, FC, WB | Shark vNAR |
| HPAB-0337-YJ-vNAR | Recombinant Shark Anti-VEGFA vNAR (V32R) | FC, ELISA, Inhib, Neut | Shark vNAR |
| NBD-0090-YJ-VHH | Camelid Anti-VEGFA Recombinant Single Domain Antibody (Nb42) | ELISA, WB, Inhib | Camelid VHH |
Recombinant Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| HPAB-0330CQ | Mouse Anti-VEGFA Recombinant Antibody (clone mAb G6-31) | ELISA, IF, Block, FuncS | Chimeric (mouse/human) IgG |
| MRO-1578-CN | Rabbit Anti-VEGFA Recombinant Antibody (clone CBACN-578) | IF, IHC, IP, FC | Rabbit IgG |
| MRO-2269-CN | Rabbit Anti-VEGFA Polyclonal Antibody (MRO-2269-CN) | WB, IF, IHC, FC | Rabbit IgG |
| HPAB-0243-YJ | Mouse Anti-VEGFA Recombinant Antibody (clone 16-3) | ELISA, Block | Mouse IgG1,κ |
| HPAB-0244-YJ | Mouse Anti-VEGFA Recombinant Antibody (clone 16-5) | ELISA, Block | Mouse IgG2b,κ |
ADCC Enhanced Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| AFC-TAB-465CQ | Afuco™ Anti-VEGFA ADCC Recombinant Antibody (Varisacumab), ADCC Enhanced | ELISA, IHC, FC, IP, IF, FuncS | ADCC enhanced antibody |
| AFC-TAB-011 | Afuco™ Anti-VEGFA ADCC Recombinant Antibody (Bevacizumab), ADCC Enhanced | FC, IP, ELISA, Neut, FuncS, IF | ADCC enhanced antibody |
Fab Fragment Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| HPAB-0715-FY-S(P) | Mouse Anti-VEGFA Recombinant Antibody (clone AB014); Fab Fragment | ELISA | Mouse Fab |
| HPAB-0950-FY-S(P) | Camelid Anti-VEGFA Recombinant Antibody; scFv Fragment (HPAB-0950-FY-S(P)) | Inhib | Camelid scFv |
| HPAB-0152-WJ-F(E) | Human Anti-VEGFA Recombinant Antibody; Fab Fragment (HPAB-0152-WJ-F(E)) | ELISA | Human Fab |
| HPAB-0169-WJ-F(E) | Human Anti-VEGFA Recombinant Antibody (clone MIL60); Fab Fragment | ELISA | Human Fab |
| HPAB-0821-WJ-F(E) | Mouse Anti-VEGFA Recombinant Antibody; Fab Fragment (HPAB-0821-WJ-F(E)) | ELISA | Mouse Fab |
scFv Fragment Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| HPAB-S0150-YC-S(P) | Human Anti-VEGFA Recombinant Antibody (clone Y0313-1); scFv Fragment | ELISA, Inhib | Humanized scFv |
| HPAB-S0151-YC-S(P) | Human Anti-VEGFA Recombinant Antibody (clone Y0238-3); scFv Fragment | ELISA, Inhib | Humanized scFv |
| HPAB-S0152-YC-S(P) | Human Anti-VEGFA Recombinant Antibody (clone Y0243-1); scFv Fragment | ELISA, Inhib | Humanized scFv |
| HPAB-1933-FY-F(E) | Human Anti-VEGFA Recombinant Antibody (clone Y0101); scFv Fragment | ELISA | Humanized scFv |
| HPAB-1956-FY-S(P) | Human Anti-VEGFA Recombinant Antibody (clone Bh21-7); scFv Fragment | IF | Humanized scFv |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for HPAB-0169-WJ. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.